Bank of America Lowers Bristol Myers Squibb (NYSE:BMY) Price Target to $67.00

09 Apr 2026, 12:28 by Teresa Graham · The Cerbat Gem

Bristol Myers Squibb (NYSE:BMY – Get Free Report) had its price objective decreased by analysts at Bank of America from $68.00 to $67.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s price target would suggest a potential upside of 12.98% from the company’s previous close.

Other analysts also recently issued research reports about the company. Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price target on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a research note on Monday, March 23rd. Piper Sandler reissued an “overweight” rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Wells Fargo & Company reissued an “outperform” rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Citigroup lifted their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Nine analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $61.71.

Read Our Latest Research Report on BMY

Bristol Myers Squibb Trading Up 0.2%

BMY stock traded up $0.10 during midday trading on Thursday, hitting $59.30. 2,013,165 shares of the company’s stock were exchanged, compared to its average volume of 13,169,014. The stock’s fifty day moving average price is $59.60 and its 200-day moving average price is $52.98. Bristol Myers Squibb has a one year low of $42.52 and a one year high of $62.89. The company has a market cap of $121.08 billion, a PE ratio of 17.19, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period in the prior year, the business earned $1.67 EPS. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts predict that Bristol Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.09% of the company’s stock.

Hedge Funds Weigh In On Bristol Myers Squibb

Institutional investors have recently bought and sold shares of the business. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb during the fourth quarter worth approximately $25,000. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb during the second quarter worth approximately $25,000. Physician Wealth Advisors Inc. increased its position in Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the last quarter. Harbor Capital Advisors Inc. increased its position in Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 313 shares during the last quarter. Finally, Bayban acquired a new position in Bristol Myers Squibb during the fourth quarter worth approximately $31,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Announced a multi‑year collaboration with Oxford BioTherapeutics to discover and develop next‑generation T‑cell engagers for solid tumors — reinforces BMS’s oncology pipeline-building strategy and reduces execution risk on early discovery. Oxford BioTherapeutics Collaboration
Positive Sentiment: Guggenheim reaffirmed a Buy on BMY with a $72 price target, supporting upside narrative from longer‑term pipeline and dividend yield. Guggenheim Buy
Positive Sentiment: Piper Sandler initiated/maintained a Buy, adding to the broker support that likely helped lift sentiment in recent sessions. Piper Sandler Buy
Neutral Sentiment: Cantor Fitzgerald raised its price target to $54 but kept a Neutral rating and cautioned that Q1 is not likely to be a dramatic catalyst — mixed signal for near‑term momentum. Cantor Fitzgerald Note
Neutral Sentiment: BofA reports that biopharma names are largely exempt from proposed pharma tariffs — sector tailwind but not a company‑specific catalyst. BofA Tariff Note
Neutral Sentiment: Recent intraday/previous-session price action showed a ~2.6% gain, reflecting the positive reaction to the collaboration and analyst activity. Price Action
Negative Sentiment: Earnings risk: previews and analyst commentary expect a double‑digit percentage decline in Q1 EPS, and BMY missed EPS in its last reported quarter — near‑term results and guidance remain key downside risks. Earnings Preview

About Bristol Myers Squibb

(Get Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.